Digital Delegation to the US

March 22-25, 2021

Turning Current Healthcare Challenges into Opportunities

Swecare with support from the Swedish-American Chambers of Commerce and together with the Ministry of Health and Social Affairs, the Embassy of Sweden in USA and Consulate General in New York, invites you to a digital delegation trip to the US, the largest healthcare and life science market in the world.

This digital delegation trip to the US is a unique opportunity to tackle the problem of accessing new contacts during the pandemic, to learn more about the US healthcare system and its priorities under the Biden administration and to raise important issues and exchange interesting ideas with relevant stakeholders. The program consists of meetings in the form of webinars, providing relevant information, digital meetings with healthcare providers, as well as a high-level forum with several breakout sessions.

Hope you will join us!
Swecare

Program

March 22 - Kick-off and first meeting                      
  • Kick-off with the delegation (tbc)

    16:00-16:25 (CET)

    Purpose: to get to know the participants in the delegation, understand their expectations and previous experience in the US market; and to set the tone for the program

    Participants: Minister Lena Hallengren, Ministry of Health and Social Affairs of Sweden, Embassy/Consulate General, Swecare, SACC and business delegation.

  • Think Tank Meeting – Kaiser Family Foundation (KFF)

    16:30-17:30 (CET)

    Meeting with Larry Levitt, Executive Vice President for Health Policy, Henry J. Kaiser Family Foundation (KFF) Profile. Kaiser Family Foundation is a non-profit organization focusing on national health issues, as well as the U.S. role in global health policy.

    Participants: Minister Lena Hallengren, Ministry of Health and Social Affairs of Sweden, Embassy/Consulate General, Swecare and business delegation

March 23 - Webinars on Regulatory and Reimbursement Issues
  • The Regulatory System for Pharma & MedTech Devices

    15:00-16:00 (CET)

    What to consider when bringing a product to the US market from Sweden
    Peter Linderoth, Partner, and Camilla Appelgren, Partner, Mannheimer Swartling law firm

    What to consider when bringing a product to the US market
    Frederick Stearns, Resident expert on FDA regulation of Drugs, Pharmaceuticals and Medical Devices, Partner, Keller and Heckman LLP (invited)

    Experiences of the US regulatory process
    Karin Eklund Vanderpol, Head of Regulatory Affairs, Oncopeptides AB

  • Reimbursement in the US Health System

    16:15-17:30 (CET)

    Overview of US Health Insurance
    Mary Scheuermann, independent consultant

    Strategies for Favorable Reimbursement in the U.S. Health System
    Steve Stranne, Partner, Polsinelli law firm (invited)

    Tips and Tricks for Reimbursement
    Philip Siberg, Co-Founder and President Coala Life, Inc

March 24 - High-level Forum                                
  • PART 1 - Introductory Session

    14:00-15:45 (CET)

    Welcome and Introduction
    H.E. Karin Olofsdotter, Ambassador of Sweden to the United States
    H.E. Lena Hallengren, Swedish Minister for Health and Social Affairs
    High-level representative, the National Institutes of Health (NIH)
    Ms. Maria Helling, CEO Swecare Foundation
    Introduction of Panel Discussions, by  Moderator Julia Manchester, Political  Reporter, the Hill:

    Introductory Panel Discussion – Cancer Care
    Dr. Professor Hans Hägglund, National Cancer Care Coordinator, Confederation of Regional Cancer Centres, Swedish Association of Local Authorities and Regions (confirmed)
    Dr. Norman E. Sharpless, Director, National Cancer Institute (Invited)

    Introductory Panel Discussion – Elderly Care
    Ms. Olivia Wigzell, Director-General, Swedish National Board of Health and Welfare
    Dr. Tricia Neuman, Senior Vice President, Henry J. Kaiser Family Foundation (KFF)

    Introductory Panel Discussion - TeleHealth
    Dr. Markus Lingman, Development Strategist, Region Halland Hospital (confirmed)
    Dr. Claus Torp Jensen, Chief Digital Officer and Head of Technology, Memorial Sloan Kettering Cancer Center

    Concluding Remarks by moderator and Introduction of Breakout Sessions

  • 15:45-16:00 Break (CET)
  • PART 2 - Parallel Breakout sessions on Cancer Care, Elderly Care and TeleHealth

    16:00-17:00 or 17:30 (CET)

    Breakout Session 1 - Cancer Care
    Moderator: TBC
    Moderator introduces the session
    Panel Discussion 3 US + 5 Swedish experts and companies
    Conclusion and end of breakout session (appr 17:00 CET)
     
    Breakout Session 2 - Elderly Care
    Moderator: TBC
    Moderator introduces the session
    Panel Discussion 3 US + 5 Swedish experts and companies
    Conclusion and end of breakout session (appr 17:00 CET)

    Breakout Session 3 - TeleHealth
    Moderator: TBC
    Moderator introduces the session
    Panel Discussion 3 US + 5 Swedish experts and companies
    Conclusion and end of breakout session (appr 17:00 CET)

March 25 14:30-17:30 (CET) - Meetings with healthcare actors and wrap-up meeting
  • Meeting with Memorial Sloan-Kettering Cancer Center (mskcc.org)

    Memorial Sloan Kettering Cancer Center — the world’s oldest and largest private cancer center — has devoted more than 135 years to exceptional patient care, innovative research, and outstanding educational programs. Today, we are one of 51 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. Close collaboration between physicians and scientists is a unique strengths, enabling the best care to patients while discovering more-effective strategies to prevent, control, and ultimately cure cancer in the future.

  • Meeting with Mayo Clinic https://www.mayoclinic.org 

    Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing.Mayo Clinic in Minnesota has been ranked as the best hospital in the USA 2020-2021. Mayo Clinic is at the top of the care pyramid; a last resort when your primary care doctor or facility cannot help you further. Mayo has a USD15 bn endowment fund and 70,000 employees worldwide. Mayo and Karolinska collaborate on education, research and innovation.

    Mayo works with Swedish venture capital fund HealthCap, and is interested in learning about and investing in Swedish health technologies, partnerships or spin-off companies.

  • Delegation wrap-up and evaluation

    A meeting to finalize the program, including evaluating the delegation trip (content and format aspects), sharing of experiences and discussions on joint and company-level follow-up activities. 

    • Presentation by Business Sweden's offer to for initial one-on-one support for companies about to enter or expand in the US market.
    • Presentation by SACC USA and SACC New England on possibilities for participation in SACC’s Trainee Program in cooperation with the Swedish Institute and AmCham; and for joining a tailormade Virtual to the New England life science ecosystem (fee-based)

Other possible follow-up events

Dates in April or May will be decided upon interest

Life Science and Health in Virginia - http://www.invest-in-usa.org/u-s-states-in-europe/2/virginia
Presentation by the state of Virginia representative in Europe, including possibility for follow-up 1-on-1 meetings – organized by US Embassy in Stockholm

Located in the center of the Mid-Atlantic’s booming life sciences cluster, Virginia provides access to key federal agencies and policy decision-makers. Virginia’s leadership position in information technology provides a launch point for growth in emerging disciplines like health IT and personalized medicine.

Life Science soft landing in Pennsylvania - https://dced.pa.gov/business-assistance/; https://sciencecenter.org/
Why Pennsylvania? Presentation by Jason Hunt, Office of International Business Development, Pennsylvania Department of Commerce and representative from University City Science Center

Pennsylvania has the infrastructure, skilled workforce and investment policies to make it an interesting place to invest, expand, and operate your business. The University City Science Center is the first and largest urban research park in the United States and help catalyze new ideas and technologies, drive economic growth, and unlock the region’s potential. 

Delegation fees

  • Swecare Members & Partners - 3 500 SEK
  • Non-Swecare Members - 5 000 SEK
  • Fee covers up to three (3) participants per organization.
  • Fee covers up to three (3) participants per organization
  • >> Registration
  • >> Registration

General Conditions for Participation in Digital Delegations trips

5 Force majeure etc  
SWECARE may cancel the activity or postpone carrying it out for a reasonable period if any obstacle to or unreasonable increase in the cost of carrying it out arises or if carrying it out would jeopardise the safety of persons or property affected by the activity, due to an event or circumstance outside SWECARE’s reasonable control (force majeure). Such events or circumstances include but are not limited to acts of violence or a risk of acts of violence of all kinds (including war, hostilities, acts of sabotage etc.), natural phenomena (earthquakes, hurricanes, floods etc.), public healht emergencies (epidemics, contagious outbreaks, quarantines), sudden events which cause injury or damage (fires, explosions etc.), labour conflicts (strike, lockout, blockade, working to rule etc.), events and interventions of an official nature (changes in the law, new legislation, a change in the exchange rate), and other unforeseen events or unforeseen consequences of foreseeable events such as lack of transport, a shortage of skilled workers, power cuts etc.  
SWECARE shall inform the participating companies in an appropriate manner as soon as possible after force majeure is deemed to exist.  
In addition to what is stated in the first paragraph of this section, the effect of invoking force majeure is that SWECARE will be absolved from economic consequences, including damages for delay in carrying out the activity or for the activity not being carried out at all or not being carried out as agreed.